The way I see it;
I'm happy they took a one time shot with the lawsuit rather than spreading the pain over the long term as it will be better for longer term results.
The continued growth in revenue is at a good consistent pace as they continue to gradually add Plasma Centers. This shapes up the company's earnings and promises more stable cash flow over time rather than the specialty programs that are synonymous with the old "lumpy" revenue.
Gross margins continue to expand due to full integration of the Paysign platform which supports the bottom line.
SG&A were higher than before, however I group SG&A's as "recurring" and "non-recurring", and when I look at the current SG&A number lots of the increase was due to non recurring expenses (if we take a long term view). The legal fees were in this SG&A and since most of this was resolved in October I don't see many more major legal fees being incurred in Q4 and 2016. Secondly, I believe lots of the research, admin and other costs involving the EU have been incurred over the past year and even if they do continue to incur some costs, if they do decide to proceed with it the set-up costs will not be re-curring. (that being said staffing costs would go up but will likely be outweighed by earnings from those operations).
Overall, I'd say its a "decent" quarter if we remove the lawsuit which was already accounted for and expected.
